$9.50
0.00%
Nasdaq, Thu, Feb 27 2025
ISIN
US73730P1084
Symbol
PSTX
Sector
Industry

Poseida Therapeutics Inc Stock price

$9.50
+0.00 0.00% 1M
+6.69 238.08% 6M
-0.10 1.04% YTD
+5.73 151.99% 1Y
+5.85 160.27% 3Y
-5.85 38.11% 5Y
-5.85 38.11% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.00 0.00%
ISIN
US73730P1084
Symbol
PSTX
Sector
Industry

Key metrics

Market capitalization $925.92m
Enterprise Value $777.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.16
P/S ratio (TTM) P/S ratio 6.14
P/B ratio (TTM) P/B ratio 10.61
Revenue growth (TTM) Revenue growth 203.18%
Revenue (TTM) Revenue $150.86m
EBIT (operating result TTM) EBIT $-62.50m
Free Cash Flow (TTM) Free Cash Flow $-17.13m
Cash position $230.85m
EPS (TTM) EPS $-0.63
P/E forward negative
P/S forward 6.40
EV/Sales forward 5.38
Short interest 5.08%
Show more

Is Poseida Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Poseida Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Poseida Therapeutics Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Poseida Therapeutics Inc:

Hold
100%

Financial data from Poseida Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
151 151
203% 203%
100%
- Direct Costs 5.47 5.47
1% 1%
4%
145 145
229% 229%
96%
- Selling and Administrative Expenses 35 35
9% 9%
24%
- Research and Development Expense 167 167
17% 17%
111%
-57 -57
57% 57%
-38%
- Depreciation and Amortization 5.47 5.47
1% 1%
4%
EBIT (Operating Income) EBIT -63 -63
54% 54%
-41%
Net Profit -61 -61
54% 54%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Poseida Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Poseida Therapeutics Inc Stock News

Positive
Proactive Investors
about 2 months ago
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche on Wednesday said it had been accepted for payment on 65 million shares in Poseida, which specialises in complex immune cell therapies for types of blood cancer.
Positive
Reuters
about 2 months ago
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.
Neutral
Business Wire
2 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones, is fair to Poseida...
More Poseida Therapeutics Inc News

Company Profile

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.

Head office United States
CEO Kristin Yarema
Employees 330
Founded 2014
Website www.poseida.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today